ACXP Acurx Pharmaceuticals, Inc.
Stock Price & Overview

$0.500.012 (+2.35%)4:00 PM 07/09/25
NASDAQ | $USD | Post-Market: $0.52 +0.02 (+3.98%) 7:52 PM

ACXP Stock Price

EPS
PE
Div Rate
Yield
Short Interest
Market Cap
Volume
Prev. Close

Quant Ranking

Latest Headlines

Ratings Summary

People Also Follow

Similar to ACXP

ETFs Holding ACXP

ACXP Company Profile

Acurx Pharmaceuticals, Inc. logo
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Employees
4
Founded
2017
Address
  • 259 Liberty Avenue
  • Staten Island, NY, 10305
  • United States
Phone Number
917 533 1469

ACXP Revenue

ACXP Earnings Per Share

Earnings Estimates

Earnings Revisions

Valuation

Profitability

Momentum

Capital Structure

Dividends

ACXP does not currently pay a dividend.

ACXP Ownership

ACXP Peers

Risk

Technicals

ACXP Transcripts

ACXP SEC Filings

ACXP Income Statement

ACXP Balance Sheet

ACXP Cash Flow Statement

ACXP Long Term Solvency

Acurx Pharmaceuticals, Inc. (ACXP) Frequently Asked Questions